Astrazeneca Share News (AZN)
AZN Share
AZN Share
AZN Share
AZN Share
AZN
AZN Share
AZN Level 2
AZN Live
AZN Broker
AZN Directors
AZN Financial
AZN
AZN Short
AZN
Last checked at -
By Nancy LapidSept 10 (Reuters) - The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that have yet to be certified by peer review.Arthritis drug cuts dea...
Read more
(Sharecast News) - AstraZeneca said on Thursday that positive results from the 'Poseidon' phase 3 trial showed 'Imfinzi', or durvalumab, and tremelimumab, when added to platinum-based chemotherapy, demonstrated a statistically-significant and clinically-meaningful improvement in overall survival and progression-free survival compared to chemotherapy alone in the first-line treatment of patients with stage four metastatic non-small cell lung cancer (NSCLC).
Read more* MHRA gives go-ahead for Pfizer, AZ booster shots* Final decision on programme still pending* Debate over if and when boosters will be needed (Adds detail, context)By Alistair SmoutLONDON, Sept 9 (Reuters) - Britain's medical regulator on Thursday...
Read moreLONDON, Sept 9 (Reuters) - Britain's medical regulator on Thursday gave the go-ahead for Pfizer and AstraZeneca's COVID-19 vaccine to be used in any future booster programme, but said any decision on boosters being used was for vaccine advisers."...
Read more
IN BRIEF: Cizzle eyes royalties after encouraging Covid drug results
Read moreLONDON BROKER RATINGS: Credit Suisse raises boohoo; Peel cuts Genus
Read moreAstraZeneca's asthma treatment trials meet primary endpoints
Read more(Sharecast News) - AstraZeneca said on Thursday that positive high-level results from the 'MANDALA' and 'DENALI' phase 3 trials of PT027, or albuterol/budesonide, at both 180/160mcg and 180/80mcg doses, met all primary endpoints.
Read more(Adds detail, context)Sept 8 (Reuters) - Europe's medicines regulator has added an extremely rare nerve-damaging disorder, Guillain-Barré syndrome, as a possible side-effect of AstraZeneca's COVID-19 vaccine, regular safety updates from the watchd...
Read more* COVAX goal held back by India export restrictions* Gavi also cites lower output by Astra, J&J* Regulatory review of Clover, Novavax shots delayed* Gavi CEO says opposes wide use of booster shots (Adds details on disease burden, GAVI quote)By Ludwi...
Read moreSept 8 (Reuters) - The COVAX vaccine-sharing facility will likely receive 1.425 billion doses of anti-COVID-19 shots from donor countries this year, down from a July estimate of 2 billion, the GAVI Vaccine Alliance said on Wednesday.Reasons for th...
Read moreHutchmed, Astra launch drug combination trial to treat lung cancer
Read more(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window)* Dunelm gains on strong FY results, upbeat 2022 profit forecast* Smiths Group gains on ICU Medical deal* FTSE 100 down 0.7%, FTSE 250 off 0...
Read moreAstraZeneca chief calls for UK to hold off booster jabs for now
Read moreSept 7 (Reuters) - AstraZeneca Plc Chief Executive Pascal Soriot said booster COVID vaccine doses may not be needed for everyone in Britain and rushing into a nationwide rollout of third doses risks piling extra pressure on the National Health Se...
Read more
Last checked at